Amgen Stock Hits Day Low of $361.39 Amid Price Pressure

Amgen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline of 3.08% on March 5, 2026, reaching an intraday low of USD 361.39. This performance contrasts with the S&P 500, which saw a slight gain of 0.78% on the same day. Over the past week, Amgen's stock has decreased by 3.09%, while the S&P 500 fell by 1.1%. In terms of longer-term performance, Amgen has shown resilience with a year-to-date increase of 12.31%, significantly outperforming the S&P 500's modest gain of 0.35%. However, over the past three years, Amgen's growth of 56.55% lags behind the S&P 500's 69.8% increase. The company maintains a strong financial position, highlighted by a high return on capital employed (ROCE) of 22.31% and a robust interest coverage ratio of 777.03. With a market capitalization of USD 202 billion, Amgen continues to be a significant entity in its industry, supported by high institutional holdings at 81.91%.